The Filing Desk

Aligos Therapeutics vs Traws Pharma

Aligos Therapeutics ALGS · Traws Pharma TRAW · Biotechnology

Traws Pharma reported revenue of $3 million in fiscal 2025, 1.3 times Aligos Therapeutics' $2 million in fiscal 2025. Aligos Therapeutics' revenue fell 39.5% in its latest year, and Traws Pharma's grew 1134.5%. Aligos Therapeutics had an operating margin of -4024.9%, against -640.7% at Traws Pharma.

Side by side

Aligos TherapeuticsTraws Pharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$3M
Revenue growth−39.5%1,134.5%
Revenue growth a year, last 5 years—69.5%
Gross margin——
Operating margin−4,024.9%−640.7%
Net margin−1,106.7%328.7%
Free cash flow—−$21M
Free cash flow margin—−744.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count57.8%439.5%
Last close$1.25$0.23
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aligos TherapeuticsTraws Pharma
Operating margin
Percent of revenue
Aligos TherapeuticsTraws Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aligos TherapeuticsTraws Pharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aligos Therapeutics and Traws Pharma pages.